A trypsin Inhibitor from tamarind reduces food intake and improves inflammatory status in rats with metabolic syndrome regardless of weight loss

• Autor(a) principal: Maciel, Bruna Leal Lima
• Data de Publicação: 2016
• Outros Autores: Carvalho, Fabiana Maria Coimbra de, Lima, Vanessa Cristina Oliveira de, Costa, Izael de Souza, Medeiros, Amanda Fernandes de, Serquiz, Alexandre Coelho, Lima, Maíra Conceição Jerônimo de Souza, Serquiz, Raphael Paschoal, Uchôa, Adriana Ferreira, Santos, Elizeu Antunes dos, Morais, Ana Heloneida de Araújo
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRN
• Texto Completo: https://repositorio.ufrn.br/handle/123456789/57689; http://dx.doi.org/10.3390/nu8100544
• topic: Obesity; Cafeteria diet; TNF-α; Glycemia

Trypsin inhibitors are studied in a variety of models for their anti-obesity and anti-inflammatory bioactive properties. Our group has previously demonstrated the satietogenic effect of tamarind seed trypsin inhibitors (TTI) in eutrophic mouse models and anti-inflammatory effects of other trypsin inhibitors. In this study, we evaluated TTI effect upon satiety, biochemical and inflammatory parameters in an experimental model of metabolic syndrome (MetS). Three groups of n = 5 male Wistar rats with obesity-based MetS received for 10 days one of the following: (1) Cafeteria diet; (2) Cafeteria diet + TTI (25 mg/kg); and (3) Standard diet. TTI reduced food intake in animals with MetS. Nevertheless, weight gain was not different between studied groups. Dyslipidemia parameters were not different with the use of TTI, only the group receiving standard diet showed lower very low density lipoprotein (VLDL) and triglycerides (TG) (Kruskal–Wallis, p < 0.05). Interleukin-6 (IL-6) production did not differ between groups. Interestingly, tumor necrosis factor-alpha (TNF-α) was lower in animals receiving TTI. Our results corroborate the satietogenic effect of TTI in a MetS model. Furthermore, we showed that TTI added to a cafeteria diet may decrease inflammation regardless of weight loss. This puts TTI as a candidate for studies to test its effectiveness as an adjuvant in MetS treatment